Myelofibrosis Trials in Seattle, United States
Conditions / Myelofibrosis / Seattle, United States
Myelofibrosis is a medical condition with active clinical research programs worldwide.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02426086 | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor | COMPLETED | PHASE2 |
| NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | RECRUITING | — |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06479135 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | RECRUITING | PHASE3 |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | COMPLETED | PHASE2 |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | RECRUITING | — |
| NCT04603495 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | TERMINATED | PHASE3 |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | COMPLETED | PHASE2 |